| Abstract | Macrolide monotherapy is currently recommended as first-line treatment of mild-to-moderate community-acquired pneumonia (CAP) in penicillin-intolerant/allergic individuals in the UK. However, resistance rates among the commonest cause, Streptococcus pneumoniae, now exceed 10% in the UK and a review of alternative agents is therefore timely. This review considers the relative merits of two agents, doxycycline and moxifloxacin, which are candidates to replace macrolides for second-line therapy of non-severe CAP. |
| Authors | H A Ludlam, D A Enoch
(Affiliation: Clinical Microbiology & Public Health Laboratory, Box 236, Addenbrooke's Hospital, Cambridge University NHS Foundation Trust, Hills Road, Cambridge, UK.)
|
| Journal | International journal of antimicrobial agents
(Int J Antimicrob Agents)
Vol. 32
Issue 2
Pg. 101-5
(Aug 2008)
ISSN: 0924-8579 Netherlands |
| PMID | 18571380
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Anti-Bacterial Agents
- Aza Compounds
- Quinolines
- moxifloxacin
- Doxycycline
|
| Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Aza Compounds
(therapeutic use)
- Clinical Trials as Topic
- Community-Acquired Infections
(drug therapy, microbiology)
- Doxycycline
(therapeutic use)
- Great Britain
- Humans
- Pneumonia, Bacterial
(drug therapy, microbiology)
- Quinolines
(therapeutic use)
- Treatment Outcome
|
